Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia

Journal of Rheumatology

Volumn 41, Issue 5, 2014, Pages 955-962

  Levy, Gerald D ^a   Rashid, Nazia ^a   Niu, Fang ^a   Cheetham, T Craig ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Chronic Kidney Disease; Hyperuricemia; Urate Lowering Therapy; Uric acid

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; FEBUXOSTAT; PROBENECID; URIC ACID; COLCHICINE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GOUT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK REDUCTION; URIC ACID BLOOD LEVEL; BLOOD; DRUG EFFECTS; FACTUAL DATABASE; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; URIC ACID;

EID: 84899725930     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131159     Document Type: Article

References (20)

1. Zhu Y, Pandya B, Choi H. Prevalence of gout and hyperuricemia in the US general population. Arthritis Rheum 2011;63:3136-41.
2. Li C, Martin B, Cummins D, Andrews L, Frech-Tamas F, Yadao A. Ambulatory resource utilization and cost for gout in the United States. Am J Pharm Benefits 2013;5:e46-e54.
3. Koebnick C, Langer-Gould A, Gould M, Chao C, Iyer R, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system comparison with US Census Bureau data. Perm J 2012;16:37-41.
4. Levey AS, Bosch JP, Lewis JB, Green T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
5. Iseki K, Oshiro S, Tozawa M, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001;24:691-7. (Pubitemid 33133783)
6. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-13.
7. Weiner D, Tighiouart H, Elsayed E, Griffith J, Salem D, Levey A. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008;19:1204-11.
8. Talaat KM, el Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007;27:435-40. (Pubitemid 47481999)
9. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982;41:59-65. (Pubitemid 12136653)
10. Siu YP, Leung KT, Tong M, Kwan T. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid levels. Am J Kidney Dis 2006;47:51-9. (Pubitemid 41828266)
11. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93.
12. Krishnamurthy A, Lazaro DM, Blumenthal DR, Gerber DA, Flom PL. The effect of allopurinol on renal function in patients with hyperuricemia: a case-control study [abstract]. Arthritis Rheum 2010;62 Suppl 10:S68.
13. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-33. (Pubitemid 350193621)
14. Mazzali M, Hughes J, Kim Y, Jefferson A, Kang D, Gordon K, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism. Hypertension 2001;38:1101-6. (Pubitemid 34252813)
15. Kang D-H, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97. (Pubitemid 35386908)
16. Stamp L, Chapman P. Gout and its comorbidities: implications for therapy. Rheumatology 2013;52:34-44
17. Juraschek SP, Miller ER III, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007-2010. Arthritis Care Res 2013;65:127-32.
18. Chen J, Pan W, Hsu C, Yeh W, Chuang S, Chen P, et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res 2013;65:133-40.
19. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46.
20. Neogi T, George J, Rekhraj S, Struthers A, Choi H, Terkeltaub R. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? Arthritis Rheum 2012;64:327-38.